Change font size Change contrast

We are partnering with third parties to develop and/or deliver their therapeutic agents, including small and large molecules and gene and cell therapies, to treat various retinal diseases.

Our drug administration technology enables routine administration to deliver drugs to specific back-of-eye tissues, including the suprachoroidal, sub-retinal and other small spaces. Our approach improves both therapeutic benefits and safety.

Our drug formulations are designed to suit the unique ocular environments into which they are delivered, resulting in optimised pharmacokinetics and pharmacodynamics as well as clinical effects lasting up to twelve months in duration.

For more information please contact us below:

* required